| NCT06788756 | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML | RECRUITING | PHASE2, PHASE3 | 2025-03-12 | 2030-08 | 2029-08 |
| NCT05319587 | Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | COMPLETED | PHASE1, PHASE2 | 2022-09-29 | 2023-08-10 | 2023-08-02 |
| NCT05195723 | Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers | COMPLETED | PHASE1 | 2022-05-11 | 2022-10-24 | 2022-10-24 |
| NCT04887298 | Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases | COMPLETED | PHASE1, PHASE2 | 2021-06-05 | 2024-08-06 | 2022-09-29 |
| NCT04702503 | Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL) | COMPLETED | PHASE1 | 2019-03-08 | 2020-11-15 | 2019-11-15 |
| NCT03388749 | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | COMPLETED | PHASE1, PHASE2 | 2018-12-17 | 2022-02-14 | 2022-02-08 |
| NCT03315039 | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | COMPLETED | PHASE1, PHASE2 | 2018-03-28 | 2020-06-20 | 2020-01-14 |
| NCT01826201 | Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis | COMPLETED | PHASE2 | 2013-03 | 2013-08 | 2013-08 |